Here’s Why argenx SE (ARGX) Rose in Q3

Core Insights - ClearBridge Investments reported that mid-cap stocks experienced growth in Q3 2025, driven by a favorable monetary policy environment and stabilizing earnings [1] - The Federal Reserve's rate cuts positively impacted small and mid-cap stocks, with value stocks outperforming growth stocks [1] - The ClearBridge Mid Cap Strategy outperformed the Russell Midcap Index, primarily due to stock selection in the consumer staples and healthcare sectors [1] Company Highlights - Argenx SE (NASDAQ:ARGX) is highlighted as a key stock in the ClearBridge Mid Cap Strategy, showing a one-month return of 9.11% and a 52-week gain of 48.48% [2] - As of November 12, 2025, Argenx SE's stock closed at $889.89 per share, with a market capitalization of $54.79 billion [2] - The company demonstrated strong second-quarter results, benefiting from the adoption of its lead therapy for autoimmune disorders and advancements in its clinical pipeline [3]